Total (n = 137) | Men (n = 68) 49.6% | Women (n = 69) 50.4% | p value | |
---|---|---|---|---|
Demographics | ||||
Age, years, mean (SD) | 52.3 (10.3) | 51.8 (10.4) | 52.8 (10.4) | 0.56 |
BMI, kg/m2 (n = 135), mean (SD) | 28.4 (4.3) | 28.5 (3.9) | 28.2 (4.8) | 0.67 |
Currently smoking, number (%) | 24 (17.5%) | 9 (13.2%) | 15 (21.7%) | 0.19 |
Living together (n = 134), number (%) | 105 (76.6%) | 55 (82.1%) | 50 (74.6%) | 0.29 |
Currently employed/working* (n = 135), number (%) | 74 (54.8%) | 43 (64.2%) | 31 (45.6%) | 0.030 |
Musculoskeletal disease measures | ||||
PsA disease duration, years, mean (SD) | 8.8 (6.8) | 8.6 (7.3) | 9.0 (6.3) | 0.70 |
CRP, mg/L, mean (SD) | 5.0 (8.3) | 6.6 (10.7) | 3.4 (4.4) | 0.024 |
TJC68, mean (SD) | 10.1 (11.1) | 7.8 (10.1) | 12.3 (11.6) | 0.023 |
SJC66, mean (SD) | 0.6 (1.0) | 0.6 (1.2) | 0.6 (0.9) | 0.91 |
MASES, range 0–13, mean (SD) | 3.0 (3.2) | 1.9 (2.5) | 4.0 (3.4) | < 0.001 |
PROs | ||||
Pain, VAS 0–100 mm, mean (SD) | 34.8 (23.3) | 30.2 (21.9) | 39.4 (24.0) | 0.021 |
Fatigue, NRS 0–10, mean (SD) | 4.2 (2.6) | 3.6 (2.5) | 4.8 (2.6) | 0.009 |
Sleep disturbance†, NRS 0–10, mean (SD) | 3.5 (2.9) | 2.8 (2.7) | 4.1 (3.0) | 0.010 |
Depression, range 1–3, mean (SD) | 1.4 (0.4) | 1.3 (0.5) | 1.5 (0.6) | 0.069 |
MHAQ, range 0–3, mean (SD) | 0.44 (0.40) | 0.36 (0.33) | 0.51 (0.44) | 0.025 |
Exercise ≥ 1 time per week, number (%) | 62 (45.3%) | 30 (44.1%) | 32 (46.4%) | 0.79 |
Comorbidity | ||||
Comorbidities (n = 136) (range 0–8) mean (SD) | 0.72 (0.93) | 0.51 (0.76) | 0.91 (1.04) | 0.012 |
Skin | ||||
PASI, range 0–72 (n = 136), mean (SD) | 2.6 (3.7) | 3.3 (4.2) | 1.9 (3.0) | 0.030 |
Skin itching, number (%) (n = 121)†† | 28 (23.1%) | 16 (26.2%) | 12 (20.0%) | 0.417 |
Treatment | ||||
Current bDMARD, number (%) (n = 136) | 44 (32.4%) | 27 (39.7%) | 17 (25.0%) | 0.067 |
Current csDMARD, number (%) | 80 (58.4%) | 43 (63.2%) | 37 (53.6%) | 0.25 |